Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.5551/jat.9225. Epub 2011 Jun 24.
Affiliations
- PMID: 21701082
- DOI: 10.5551/jat.9225
Free article
Randomized Controlled Trial
Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial
Hiroki Ueno et al. J Atheroscler Thromb. 2011.
Free article
Abstract
Aim: A recent clinical trial showed the preventive effect of cilostazol on cerebrovascular diseases. We compared the effects of cilostazol with aspirin on circulating endothelial progenitor cells (EPCs), a surrogate marker for cardiovascular disease, and lipid metabolism in a randomized controlled trial (UMIN000000537).
Methods: Forty-nine diabetic outpatients with leukoaraiosis or asymptomatic old cerebral infarction were enrolled in the study with written informed consent. They were randomly assigned to a cilostazol (200 mg daily, n= 24) or aspirin group (100 mg daily, n= 25), and followed for 16 weeks. Changes in circulating CD34(+) CD45(low) CD133(+) VEGFR2(+) EPCs (ΔEPC) were a primary endpoint. Changes in CD34(+) CD45(low) CD133(+) progenitor cells (ΔPC), p-selectin-positive platelet, platelet-monocyte binding measured by flow cytometry, LDL-, HDL-, small dense LDL (sdLDL)-cholesterol and triacylglycerol were the secondary endpoints.
Results: Twenty patients in each group completed the study. ΔEPC were significantly higher in the cilostazol group than aspirin group at 16 weeks, while ΔPC were already significantly higher at 4 weeks in the cilostazol group. Changes in p-selectin-positive platelets and platelet-monocyte binding were similar in both groups. The cilostazol group showed significantly less sdLDL- and higher HDL-cholesterol than the aspirin group at both 4 and 16 weeks. ΔEPC were significantly and inversely correlated with changes of sdLDL, while positively with those of HDL. Analysis of covariance showed that a significant relation of ΔEPCs with cilostazol treatment was confounded by changes in HDL- and sdLDL-cholesterol.
Conclusion: Cilostazol increases circulating EPCs and decreases small-dense LDL in diabetic patients with cerebral ischemia.
Similar articles
- Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique.
Lee SJ, Lee JS, Choi MH, Lee SE, Shin DH, Hong JM. Lee SJ, et al. BMC Neurol. 2017 Aug 29;17(1):169. doi: 10.1186/s12883-017-0950-y. BMC Neurol. 2017. PMID: 28851320 Free PMC article. Clinical Trial. - Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.
Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, Fan D, Zeng J, Wong K, Lu C, Xiao J, Yao C; Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention cooperation investigators. Huang Y, et al. Lancet Neurol. 2008 Jun;7(6):494-9. doi: 10.1016/S1474-4422(08)70094-2. Epub 2008 May 2. Lancet Neurol. 2008. PMID: 18456558 Clinical Trial. - Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats.
Oyama N, Yagita Y, Kawamura M, Sugiyama Y, Terasaki Y, Omura-Matsuoka E, Sasaki T, Kitagawa K. Oyama N, et al. Stroke. 2011 Sep;42(9):2571-7. doi: 10.1161/STROKEAHA.110.609834. Epub 2011 Jul 28. Stroke. 2011. PMID: 21799161 - [Protective effects of cilostazol against transient focal cerebral ischemia and hemorrhagic transformation].
Ishiguro M, Hara H. Ishiguro M, et al. Yakugaku Zasshi. 2011 Apr;131(4):513-21. doi: 10.1248/yakushi.131.513. Yakugaku Zasshi. 2011. PMID: 21467790 Review. Japanese. - Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Niu PP, Guo ZN, Jin H, Xing YQ, Yang Y. Niu PP, et al. BMJ Open. 2016 Mar 17;6(3):e009013. doi: 10.1136/bmjopen-2015-009013. BMJ Open. 2016. PMID: 26988347 Free PMC article. Review.
Cited by
- Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event.
Huh JH, Seok H, Lee BW, Kang ES, Lee HC, Cha BS. Huh JH, et al. Endocrine. 2014 Sep;47(1):138-45. doi: 10.1007/s12020-013-0120-y. Epub 2014 Jan 1. Endocrine. 2014. PMID: 24381128 - Endothelial progenitor cells in ischemic stroke: an exploration from hypothesis to therapy.
Li YF, Ren LN, Guo G, Cannella LA, Chernaya V, Samuel S, Liu SX, Wang H, Yang XF. Li YF, et al. J Hematol Oncol. 2015 Apr 11;8:33. doi: 10.1186/s13045-015-0130-8. J Hematol Oncol. 2015. PMID: 25888494 Free PMC article. Review. - Cilostazol for intermittent claudication.
Brown T, Forster RB, Cleanthis M, Mikhailidis DP, Stansby G, Stewart M. Brown T, et al. Cochrane Database Syst Rev. 2021 Jun 30;6(6):CD003748. doi: 10.1002/14651858.CD003748.pub5. Cochrane Database Syst Rev. 2021. PMID: 34192807 Free PMC article. - Cilostazol for intermittent claudication.
Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Bedenis R, et al. Cochrane Database Syst Rev. 2014 Oct 31;2014(10):CD003748. doi: 10.1002/14651858.CD003748.pub4. Cochrane Database Syst Rev. 2014. PMID: 25358850 Free PMC article. Updated. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous